Exagen
XGN
61 hedge funds and large institutions have $29M invested in Exagen in 2026 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 22 reducing their positions, and 26 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 22
7.45% less ownership
Funds ownership: 47.66% → 40.21% (-7.4%)
24% less funds holding
Funds holding: 80 → 61 (-19)
56% less capital invested
Capital invested by funds: $65.7M → $29M (-$36.7M)
69% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 26
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCNMGF
Nano-Cap New Millennium Growth Fund
Staten Island,
New York
|
+$1.3M |
| 2 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$1.26M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.06M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$845K |
| 5 |
Squarepoint
New York
|
+$777K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$1.53M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.17M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$1.14M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.07M |
| 5 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$1.06M |
XGN Hedge Fund Activity: Q1 2026 in Review
61 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Exagen (XGN) for Q1 2026, worth a combined $29M — down 56% from $65.7M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of XGN and 8 opened new positions — a net loss of 18 holders — while 22 trimmed existing stakes and 25 added.
The largest buyer was Nano-Cap New Millennium Growth Fund, adding an estimated $1.3M. The largest seller was RTW Investments, cutting an estimated $1.53M.
- 61 institutional investors held Exagen (XGN) as of Q1 2026, down from 80 in Q4 2025.
- Funds reported $29M of Exagen stock for Q1 2026, down 56% quarter-over-quarter.
- 8 funds opened new Exagen positions in Q1 2026 and 26 closed out, a net change of -18 holders.
- The largest Exagen buyer in Q1 2026 was Nano-Cap New Millennium Growth Fund, an estimated $1.3M added.
- The largest Exagen seller in Q1 2026 was RTW Investments, an estimated $1.53M sold.
Based on aggregated 13F filings for Q1 2026.